Pittock, S., Barnett, M., Bennett, J., Berthele, A., de Sèze, J., Levy, M., . . . Kim, H. (2023). P-53 Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Outcomes from the phase 3 CHAMPION-NMOSD trial. Clinical neurophysiology, 148, e32. https://doi.org/10.1016/j.clinph.2023.02.070
Citace podle Chicago (17th ed.)Pittock, S., et al. "P-53 Efficacy and Safety of Ravulizumab in Adults with Anti-aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Outcomes from the Phase 3 CHAMPION-NMOSD Trial." Clinical Neurophysiology 148 (2023): e32. https://doi.org/10.1016/j.clinph.2023.02.070.
Citace podle MLA (9th ed.)Pittock, S., et al. "P-53 Efficacy and Safety of Ravulizumab in Adults with Anti-aquaporin-4 Antibody-positive Neuromyelitis Optica Spectrum Disorder: Outcomes from the Phase 3 CHAMPION-NMOSD Trial." Clinical Neurophysiology, vol. 148, 2023, p. e32, https://doi.org/10.1016/j.clinph.2023.02.070.